LEI: 213800H188ZDCWWXFA21
The following amendments have been made to the
'Director/PDMR Shareholding' announcement released on 24 October
2024 at 14:33 under RNS No 5203J.
In paragraph (a) "1740,740" has been changed to
"174,740" and "£20.015 pence" changed to "20.015 pence".
All other details remain unchanged.
The full amended text is shown
below.
Creo Medical Group plc
("Creo" or the
"Company")
Director/PDMR Share
Dealings
Creo Medical Group plc (AIM: CREO), a medical
device company focused on the emerging field of surgical endoscopy
for cancer and pre-cancer patients, announce that on
24 October 2024, Richard Rees, CFO has:
a) in order to effect a "Bed and
ISA" transaction, sold 174,740 ordinary shares in the Company
("Ordinary Shares") at a price of 20 pence per Ordinary Share from
his Dealing Account and then repurchased into his Individual
Savings Account ("ISA")
98,000 Ordinary Shares at a price of 20.015 pence per Ordinary
Share; and
b) Rachel Rees, a person closely
associated with him ("PCA")
has purchased the remaining 76,740 Ordinary Shares into her
ISA.
Following these transactions, there has been no
change in the number of shares in which Richard Rees has an
interest.
This announcement, including the notification
below, is made in accordance with the requirements of the UK Market
Abuse Regulation.
For
further information please contact:
|
Creo Medical
Group plc
|
www.creomedical.com
|
|
Richard Craven, Company Secretary
|
Via Walbrook
PR
|
|
|
|
|
Cavendish
Capital Markets Limited
(Nominated
Adviser, Joint Bookrunner and Joint Broker)
|
+44 (0)20 7220
0500
|
|
Stephen Keys / Camilla Hume / George Lawson
(NOMAD)
|
|
|
Michael Johnson (Sales)
|
|
|
|
|
|
Deutsche Numis
(Joint Bookrunner and Joint Broker)
Freddie Barnfield / Duncan Monteith / Euan
Brown
William Baunton (ECM)
|
+44 (0)20
7260 1000
|
|
|
|
|
Walbrook PR
Ltd
|
Tel: +44 (0)20 7933
8780 or creo@walbrookpr.com
|
|
Paul McManus / Alice Woodings
Philip Marriage
|
Mob: +44 (0)7980 541
893 / +44 (0)7407 804 654
Mob: +44 (0)7867 984
082
|
|
|
| |
About Creo
Medical
Creo Medical is a medical device company
focused on the development and commercialisation of minimally
invasive electrosurgical devices, bringing advanced energy to
endoscopy.
The Company's vision is to improve patient
outcomes through the development and commercialisation of a suite
of electrosurgical medical devices, each enabled by CROMA, powered
by Kamaptive. The Group has developed the CROMA powered by
Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically
adapt to patient tissue during procedures such as resection,
dissection, coagulation and ablation of tissue. Kamaptive
technology provides clinicians with increased flexibility,
precision and controlled surgical solutions. CROMA currently
delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for
controlled coagulation and ablation via a single accessory port.
This technology, combined with the Group's range of patented
electrosurgical devices, is designed to provide clinicians with
flexible, accurate and controlled clinical solutions. The Directors
believe the Company's technology can impact the landscape of
surgery and endoscopy by providing a safer, less-invasive and more
cost-efficient option for procedures.
For more information, please refer to the
website www.creomedical.com
NOTIFICATION
AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH
THEM
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Richard Rees
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification/Amendment
|
Initial Notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Creo Medical Group plc
|
|
b)
|
LEI
|
213800H188ZDCWWXFA21
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Ordinary shares of £0.001 each
|
|
|
Identification code
|
GB00BZ1BLL44
|
|
b)
|
Nature of the transaction
|
1. Sale of
Ordinary Shares
|
|
c)
|
Price(s) and volumes(s)
|
Price(s)
|
Volume(s)
|
|
£0.20
|
174,740
|
|
d)
|
Aggregated information
|
N/A single transaction
|
|
|
Aggregated volume
|
N/A single transaction
|
|
|
Price
|
N/A single transaction
|
|
e)
|
Date of the transaction
|
24 October 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Richard Rees
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification/Amendment
|
Initial Notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Creo Medical Group plc
|
|
b)
|
LEI
|
213800H188ZDCWWXFA21
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Ordinary shares of £0.001 each
|
|
|
Identification code
|
GB00BZ1BLL44
|
|
b)
|
Nature of the transaction
|
1. Purchase
of Ordinary Shares via his ISA
|
|
c)
|
Price(s) and volumes(s)
|
Price(s)
|
Volume(s)
|
|
£0.20015
|
98,000
|
|
d)
|
Aggregated information
|
N/A single transaction
|
|
|
Aggregated volume
|
N/A single transaction
|
|
|
Price
|
N/A single transaction
|
|
e)
|
Date of the transaction
|
24 October 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Rachel Rees
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
PCA to Richard Rees, CFO
|
|
b)
|
Initial notification/Amendment
|
Initial Notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Creo Medical Group plc
|
|
b)
|
LEI
|
213800H188ZDCWWXFA21
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Ordinary shares of £0.001 each
|
|
|
Identification code
|
GB00BZ1BLL44
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volumes(s)
|
Price(s)
|
Volume(s)
|
|
£0.20015
|
76,740
|
|
d)
|
Aggregated information
|
N/A single transaction
|
|
|
Aggregated volume
|
N/A single transaction
|
|
|
Price
|
N/A single transaction
|
|
e)
|
Date of the transaction
|
24 October 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
